Craig Stephen Mickanin

This inventor holds 4 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: Novartis Ag, Intellia Therapeutics, Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Craig Stephen Mickanin. Retrieved from https://idiyas.com/inventor/craig-stephen-mickanin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 5.2

ph-index = 1

Forward Citations = 6(Granted Patents)

Location History:

Cambridge, MA (US) (2017)
Hopkinton, MA (US) (2022 - 2024)

Company Filing History:

Intellia Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559748 - COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES (2026-02-24),

2. 12037583 - Compositions and methods for immunooncology (2024-07-16),

3. 11466271 - Compositions and methods for the treatment of hemoglobinopathies (2022-10-11),

4. 9850543 - Biomarkers associated with BRM inhibition (2017-12-26),

Title: Innovations by Craig Stephen Mickanin

Introduction

Craig Stephen Mickanin is an accomplished inventor based in Hopkinton, MA (US). He holds a total of three patents, showcasing his contributions to the field of immunooncology and the treatment of hemoglobinopathies. His work reflects a commitment to advancing medical science through innovative solutions.

Latest Patents

Mickanin's latest patents include "Compositions and methods for immunooncology," which focuses on genome editing systems, reagents, and methods aimed at enhancing immunooncology treatments. Another significant patent is "Compositions and methods for the treatment of hemoglobinopathies," which also involves genome editing systems and methods designed to address hemoglobin disorders.

Career Highlights

Throughout his career, Mickanin has worked with notable companies such as Novartis AG and Intellia Therapeutics, Inc. His experience in these organizations has contributed to his expertise in developing cutting-edge medical technologies.

Collaborations

Mickanin has collaborated with talented individuals in his field, including Yi Yang and Zainab Jagani. These partnerships have likely enriched his research and innovation efforts.

Conclusion

Craig Stephen Mickanin's work exemplifies the impact of innovative thinking in the medical field. His patents and collaborations highlight his dedication to improving healthcare through advanced technologies.

Profile summary based on public USPTO records.